The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

BioMS and Lilly Terminate Dirucotide Agreement

Not surprising, given the failure of the SPMS trial (etc.) in July, but Eli Lilly and BioMS have terminated their license and collaboration agreement, with “all commercial rights to dirucotide … returned to BioMS.”  No indication from the press release where BioMS is headed, just that they’re “completing [their] review of the additional dirucotide clinical data and assessing the strategic options available.”  Sigh.

Bookmark and Share

One response to “BioMS and Lilly Terminate Dirucotide Agreement

  1. Pingback: BioMS’ New Directions — Buys 48% of Spectral Diagnostics, Still Has Dry Powder « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Get every new post delivered to your Inbox.

Join 128 other followers